TUESDAY, Jan. 11 (HealthDay News) -- Among heart failure patients with reduced left ventricular ejection fraction, those taking candesartan had a lower one-year and five-year mortality risk than those taking losartan, according to a study published in the Jan. 12 issue of the Journal of the American Medical Association.
Maria Eklind-Cervenka, M.D., of South Hospital in Stockholm, Sweden, and colleagues investigated all-cause mortality in 5,139 patients in a heart failure registry who had been treated with candesartan or losartan. They analyzed all-cause mortality at one and five years, by angiotensin II receptor blocker agent and determined survival predictors.
The researchers found that heart failure patients treated with losartan had a hazard ratio for mortality of 1.43 compared with those receiving candesartan. One year survival was 90 percent for patients receiving cadesartan and 83 percent for those receiving losartan. Five year survival was 61 and 44 percent for candesartan and losartan, respectively. These differences were significant, even after adjusting for propensity scores and numerous clinical variables and after stratification and quantification of potential residual confounders.
"In conclusion, our findings suggest that candesartan is associated with less all-cause mortality than losartan. However, clinical decision making should await supportive evidence of this observed association," the authors write.
Several authors received financial support from pharmaceutical companies.
Abstract
Full Text (subscription or payment may be required)
